| NCT03901339 | Gilead Sciences | Metastatic Breast Cancer | 2019-05-08 | PHASE3 |
| NCT06170788 | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer (NSCLC) | 2023-12-15 | PHASE3 |
| NCT04617522 | Gilead Sciences | Advanced or Metastatic Solid Tumor|Liver Failure | 2021-04-06 | PHASE1 |
| NCT06827613 | Marengo Therapeutics, Inc. | Triple Negative Locally Advanced Non-resectable Breast Cancer|HR&addition;, HER2-, Advanced Breast Cancer | 2025-03-24 | PHASE1|PHASE2 |
| NCT07339059 | Bindu R Potugari|Gilead Sciences | Small Cell Lung Cancer ( SCLC )|Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 2026-06-01 | PHASE2 |
| NCT07329322 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 2026-03-30 | PHASE2 |
| NCT06952504 | Merck Sharp & Dohme LLC | Endometrial Cancer | 2025-05-22 | PHASE3 |
| NCT06204614 | Brigham and Women´s Hospital | Muscle Invasive Bladder Urothelial Carcinoma | 2024-02-14 | EARLY_PHASE1 |
| NCT06665178 | British Columbia Cancer Agency|Gilead Sciences | Breast Cancer | 2025-03-31 | PHASE2 |
| NCT07471776 | Fudan University | Metastatic Breast Cancer ( HER2 Negative) | 2026-03-11 | PHASE2 |
| NCT07458113 | Yale University|Johns Hopkins University|Merck Sharp & Dohme LLC|Translational Breast Cancer Research Consortium | Metastatic Triple Negative Breast Cancers | 2026-05 | PHASE2 |
| NCT06706219 | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer (Stage III) | 2026-05-10 | PHASE2 |
| NCT06263543 | Reshma L. Mahtani, D.O.|Gilead Sciences | Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Hormone-receptor-positive Breast Cancer|Human Epidermal Growth Factor 2 Low Breast Cancer | 2024-06-17 | PHASE2 |
| NCT06161532 | National Cancer Institute (NCI) | Small Cell Carcinoma of the Bladder|Small Cell Carcinoma of the Urinary Tract|Squamous Cell Carcinoma of the Bladder|Squamous Cell Carcinoma of the Urinary Tract|Primary Adenocarcinoma of the Bladder|Primary Adenocarcinoma of the Urinary Tract|Renal Medullary Carcinoma|Squamous Cell Carcinoma of the Penis | 2024-08-01 | PHASE2 |
| NCT07216703 | Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation | Cervical Cancer | 2026-01-19 | PHASE3 |
| NCT06612203 | MedSIR|Debiopharm International SA|Gilead Sciences | Advanced Breast Cancer | 2025-01-17 | PHASE1|PHASE2 |
| NCT06178588 | University of Kansas Medical Center|National Cancer Institute (NCI) | Locally Advanced Cholangiocarcinoma|Metastatic Cholangiocarcinoma|Recurrent Cholangiocarcinoma|Stage III Hilar Cholangiocarcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hilar Cholangiocarcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | 2024-02-01 | PHASE2 |
| NCT02574455 | Gilead Sciences | Breast Cancer | 2017-11-07 | PHASE3 |
| NCT06524544 | National Cancer Institute (NCI) | Locally Advanced Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Unresectable Urothelial Carcinoma | 2025-12-02 | PHASE3 |
| NCT06074588 | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer (NSCLC) | 2023-11-12 | PHASE3 |
| NCT05101096 | Gilead Sciences | Advanced Solid Tumor|Metastatic Triple-Negative Breast Cancer|HR&addition;+HER2- Metastatic Breast Cancer|Metastatic Urothelial Cancer | 2021-10-20 | PHASE1|PHASE2 |
| NCT06236269 | SOLTI Breast Cancer Research Group | Breast Cancer Stage IV | 2024-03-15 | PHASE2 |
| NCT04454437 | Gilead Sciences | Metastatic Triple-negative Breast Cancer | 2020-10-23 | PHASE2 |
| NCT03971409 | Laura Huppert, MD, BA|Translational Breast Cancer Research Consortium|Hoosier Cancer Research Network|Array BioPharma|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|Gilead Sciences | Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma | 2019-07-08 | PHASE2 |
| NCT05633667 | Gilead Sciences|Arcus Biosciences, Inc. | Lung Cancer|Advanced or Metastatic Non-Small-Cell Lung Cancer|Resectable Non-Small-Cell Lung Cancer | 2023-03-16 | PHASE2 |
| NCT06462092 | Guangzhou Medical University | Leptomeningeal Metastases | 2026-01-01 | PHASE1|PHASE2 |
| NCT07368543 | Fudan University | Metastatic Breast Cancer | 2026-01-16 | PHASE2 |
| NCT05226117 | IRCCS San Raffaele|High Research | Urothelial Carcinoma | 2022-03-23 | PHASE2 |
| NCT06991790 | Peking University Cancer Hospital & Institute | TNBC | 2025-05-01 | |
| NCT06243393 | University Hospital Heidelberg | Metastatic Colorectal Cancer | 2024-04-19 | PHASE2|PHASE3 |
| NCT06055465 | Chinese University of Hong Kong | Lung Cancer | 2024-02-28 | PHASE2 |
| NCT04230109 | Massachusetts General Hospital|Gilead Sciences | Invasive Breast Cancer|Triple Negative Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|HER2-negative Breast Cancer | 2020-07-14 | PHASE2 |
| NCT07063212 | Memorial Sloan Kettering Cancer Center|Gilead Sciences | Squamous Cell Carcinoma of Head and Neck|Sinus Cancer|Nasal Cavity Cancer|Oral Cavity Cancer|Oropharynx Cancer|Hypopharynx Cancer|Larynx Cancer|Oral Squamous Cell Carcinoma|Oropharynx Squamous Cell Carcinoma|Hypopharynx Squamous Cell Carcinoma|Larynx Squamous Cell Carcinoma|HPV Positive Oropharyngeal Squamous Cell Carcinoma | 2025-07-02 | PHASE2 |
| NCT06923826 | National University Hospital, Singapore|Gilead Sciences | Salivary Gland Cancer|Thyroid Cancer | 2025-04-15 | PHASE2 |
| NCT03547973 | Gilead Sciences|Merck KGaA, Darmstadt, Germany | Metastatic Urothelial Cancer | 2018-08-13 | PHASE2 |
| NCT06963905 | Yale University|Bristol-Myers Squibb | Metastatic Triple-negative Breast Cancer | 2025-12-29 | PHASE1|PHASE2 |
| NCT07068542 | Zhejiang Provincial People´s Hospital | Advanced Thyroid Carcinoma|Radioiodine-refractory Differentiated Thyroid Cancer|Poorly Differentiated Thyroid Carcinoma | 2025-07-01 | NA |
| NCT05113966 | G1 Therapeutics, Inc. | Triple Negative Breast Cancer | 2021-12-08 | PHASE2 |
| NCT07323056 | Shanghai Pulmonary Hospital, Shanghai, China | EGFR-mutant Non-small Cell Lung Cancer|Potentially Resectable | 2026-01-01 | PHASE2 |
| NCT06616987 | Yeon Hee Park | Breast Cancer Metastatic | 2025-07-03 | PHASE2 |
| NCT07109284 | West China Hospital | ER&addition;HER2- Breast Cancer | 2025-09 | PHASE2 |
| NCT07244874 | Tianjin Medical University Cancer Institute and Hospital|Southwest Hospital, China | TNBC - Triple-Negative Breast Cancer|PD-L1 Positive | 2025-12-01 | PHASE2 |
| NCT04579224 | National Cancer Institute (NCI) | Metastatic Bladder Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Refractory Bladder Urothelial Carcinoma|Refractory Urothelial Carcinoma|Stage IV Bladder Cancer AJCC v8 | 2021-06-28 | PHASE3 |
| NCT07348861 | Zheng Min|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.|Qilu Pharmaceutical Co., Ltd. | Cervical Cancer | 2026-02-01 | PHASE2 |
| NCT06682728 | University of California, Irvine|Gilead Sciences | Urothelial Carcinoma|Muscle-invasive Bladder Cancer | 2024-11-15 | PHASE2 |
| NCT06469944 | Merck Sharp & Dohme LLC | Gastroesophageal Junction|Gastroesophageal Adenocarcinoma|Esophageal Neoplasms|Esophageal Cancer | 2024-09-20 | PHASE1|PHASE2 |
| NCT07139470 | Tianjin Medical University Cancer Institute and Hospital | Triple Negative Breast Cancer | 2025-08-15 | PHASE1|PHASE2 |
| NCT05089734 | Gilead Sciences | Non-Small Cell Lung Cancer | 2021-11-17 | PHASE3 |
| NCT03995706 | The University of Texas Health Science Center at San Antonio|Gilead Sciences | Glioblastoma | 2019-07-17 | EARLY_PHASE1 |
| NCT03337698 | Hoffmann-La Roche | Carcinoma, Non-Small-Cell Lung | 2017-12-27 | PHASE1|PHASE2 |
| NCT07011654 | M.D. Anderson Cancer Center|Y-mAbs Therapeutics | Metastatic Triple-Negative Breast Cancer | 2025-09-19 | PHASE1|PHASE2 |
| NCT05552001 | UNICANCER|Gilead Sciences | Triple Negative Breast Cancer|Metastatic Breast Cancer | 2023-10-05 | PHASE3 |
| NCT03606967 | National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma | 2021-04-13 | PHASE2 |
| NCT07286149 | Merck Sharp & Dohme LLC|Daiichi Sankyo | Lung Neoplasm Malignant | 2026-04-30 | PHASE1|PHASE2 |
| NCT06409390 | H. Lee Moffitt Cancer Center and Research Institute | Metastatic Breast Cancer | 2024-08-14 | PHASE2 |
| NCT06100874 | Adrienne G. Waks|Gilead Sciences | Her 2 Positive Breast Cancer|Breast Cancer Female|Breast Cancer Metastatic | 2023-11-20 | PHASE2 |
| NCT07561463 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Pancreatic Ductal Adenocarcinoma (PDAC) | 2026-04-01 | PHASE2 |
| NCT06329869 | National Taiwan University Hospital|Gilead Sciences | Esophageal Squamous Cell Carcinoma | 2024-08-01 | PHASE2 |
| NCT06311214 | National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm | 2025-03-18 | PHASE2 |
| NCT04863885 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Gilead Sciences | Metastatic Urothelial Carcinoma | 2021-04-30 | PHASE1|PHASE2 |
| NCT06248515 | Georgetown University|Gilead Sciences | Thymoma|Thymic Carcinoma | 2024-04-25 | PHASE2 |
| NCT07054242 | Yantai Yuhuangding Hospital|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Neoadjuvant Therapy|Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer | 2025-10-30 | PHASE2 |
| NCT04639986 | Gilead Sciences | Metastatic Breast Cancer | 2020-11-23 | PHASE3 |
| NCT03964727 | Gilead Sciences | Metastatic Solid Tumor | 2019-10-15 | PHASE2 |
| NCT05633654 | Gilead Sciences|Alliance Foundation Trials, LLC.|NSABP Foundation Inc|GBG Forschungs GmbH | Triple Negative Breast Cancer | 2022-12-12 | PHASE3 |
| NCT03725761 | University of Wisconsin, Madison|National Cancer Institute (NCI)|Gilead Sciences | Prostate Cancer | 2018-10-24 | PHASE2 |
| NCT07018427 | Peking University Cancer Hospital & Institute | Breast Neoplasms|Triple Negative Breast Cancer|HR&addition;, HER2-, Advanced Breast Cancer|Breast Cancer | 2023-05-01 | |
| NCT06132958 | Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation | Endometrial Cancer | 2023-12-06 | PHASE3 |
| NCT06040970 | Icahn School of Medicine at Mount Sinai | Ovarian Cancer|Malignant Neoplasm of Uterus | 2024-10-23 | PHASE1|PHASE2 |
| NCT07088211 | Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University | Recurrent+Metastatic Head and Neck Squamous Cell Carcinoma | 2025-07-31 | PHASE2 |
| NCT05601440 | Canadian Cancer Trials Group | Breast Cancer | 2023-06-13 | PHASE2 |
| NCT06133517 | Fundación para el Progreso de la Oncología en Cantabria|Apices Soluciones S.L. | Urothelial Bladder Carcinoma | 2025-01-20 | PHASE2 |
| NCT06401824 | Maastricht University Medical Center|Gilead Sciences | NSCLC Stage IV|Brain Metastases, Adult | 2025-04-24 | PHASE2 |
| NCT07521670 | National Cancer Centre, Singapore|Merck Sharp & Dohme LLC|National Cancer Center, Japan | Recurrent Adenoid Cystic Carcinoma|Adenoid Cystic Carcinoma Metastatic|Papillary Thyroid Carcinoma | 2026-05 | PHASE2 |
| NCT05382299 | Gilead Sciences | Triple Negative Breast Cancer|PD-L1 Negative | 2022-07-20 | PHASE3 |
| NCT05319730 | Merck Sharp & Dohme LLC | Esophageal Squamous Cell Carcinoma | 2023-05-16 | PHASE1|PHASE2 |
| NCT06528483 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Gilead Sciences | Bladder Cancer|Bladder Urothelial Carcinoma|Bladder Neoplasm|Muscle-Invasive Bladder Carcinoma | 2024-12-02 | PHASE2 |
| NCT07128693 | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 2025-09 | PHASE2 |
| NCT04927884 | ImmunityBio, Inc. | Advanced Triple Negative Breast Cancer | 2021-09-08 | PHASE1|PHASE2 |
| NCT05838521 | Yale University|Gilead Sciences | Cervical Cancer | 2023-06-02 | PHASE2 |
| NCT05840211 | Gilead Sciences | Locally Advanced or Unresectable Metastatic Breast Cancer|Stage IV Breast Cancer | 2023-05-08 | PHASE3 |
| NCT06483334 | Merck Sharp & Dohme LLC | Metastatic Urothelial Carcinoma|Locally Advanced Urothelial Carcinoma | 2024-07-17 | PHASE1|PHASE2 |
| NCT07492914 | West China Hospital | Resectable Head and Neck Squamous Cell Carcinoma | 2026-03-20 | PHASE2 |
| NCT06431633 | Fundación GECP | Lung Diseases|Carcinoma, Non-Small-Cell Lung|Resectable Lung Non-Small Cell Carcinoma | 2025-02-04 | PHASE3 |
| NCT06824467 | Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | 2025-04-09 | PHASE3 |
| NCT06865677 | National Cancer Institute (NCI) | Recurrent Platinum Resistant Epithelial Ovarian Carcinoma|Recurrent Epithelial Endometrial Carcinoma|Recurrent Epithelial Cervical Carcinoma | 2025-06-09 | PHASE2 |
| NCT07153965 | Tianjin Medical University Cancer Institute and Hospital | Triple Negative Breast Cancer (TNBC)|PD-L1 Positive | 2025-09-01 | PHASE2 |
| NCT06235216 | Grupo Espanol de Tumores Neuroendocrinos|MFAR|Gilead Sciences | Differentiated Thyroid Cancer|Anaplastic Thyroid Cancer | 2024-09-13 | PHASE2 |
| NCT07343453 | Sun Yat-sen University | Thymic Epithelial Tumors|Advanced Stage|Second-line Therapy | 2025-12-22 | PHASE2 |
| NCT05119907 | Gilead Sciences | Solid Tumor | 2021-10-12 | PHASE2 |
| NCT07007780 | Xijing Hospital | Triple -Negative Breast Cancer | 2025-08-20 | PHASE2 |
| NCT04647916 | SWOG Cancer Research Network|National Cancer Institute (NCI)|Gilead Sciences | Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic HER2 Negative Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Prognostic Stage IV Breast Cancer AJCC v8 | 2021-06-08 | PHASE2 |
| NCT01631552 | Gilead Sciences | Gastric Adenocarcinoma|Esophageal Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Ovarian Epithelial Cancer|Carcinoma Breast Stage IV|Hormone-refractory Prostate Cancer|Head and Neck Cancers- Squamous Cell|Renal Cell Cancer|Urinary Bladder Neoplasms|Cervical Cancer|Endometrial Cancer|Glioblastoma Multiforme|Triple Negative Breast Cancer|Pancreatic Cancer | 2012-12-17 | PHASE1|PHASE2 |
| NCT04434040 | Dana-Farber Cancer Institute|Genentech, Inc.|Stand Up To Cancer | Breast Cancer|Triple Negative Breast Cancer|Residual Cancer|Circulating Tumor DNA | 2020-07-02 | PHASE2 |
| NCT03992131 | pharmaand GmbH|Gilead Sciences | Ovarian Cancer|Triple-negative Breast Cancer|Urothelial Carcinoma|Solid Tumor | 2019-06-28 | PHASE1|PHASE2 |
| NCT06788912 | Merck Sharp & Dohme LLC | Lung Neoplasm Malignant | 2025-03-20 | PHASE2 |
| NCT07548060 | Tianjin Medical University Cancer Institute and Hospital | NSCLC Stage IV|EGFR Gene Mutation | 2026-02-01 | PHASE2 |
| NCT06926920 | Gilead Sciences | Triple Negative Breast Cancer | 2025-04-30 | PHASE1|PHASE2 |
| NCT05675579 | M.D. Anderson Cancer Center|Gilead Sciences | Breast Cancer | 2023-05-23 | PHASE2 |
| NCT07151586 | UNICANCER | Triple Negative Breast Neoplasms|Neoplasm Metastasis|HER 2 Low-expressing Breast Cancer | 2025-10 | PHASE2 |
| NCT05520723 | MedSIR|Gilead Sciences | Triple Negative Breast Cancer|Breast Cancer|Advanced HR&addition;+HER2- Breast Cancer | 2023-02-06 | PHASE2 |
| NCT06462079 | Guangzhou Medical University | Brain Metastasis | 2024-06-15 | PHASE2 |
| NCT05143229 | University of Kansas Medical Center|Novartis Pharmaceuticals|Gilead Sciences | Breast Cancer | 2022-03-28 | PHASE1 |
| NCT07134556 | MedSIR | Triple Negative Breast Cancer|PDL-1 Positive | 2026-04 | PHASE2 |
| NCT04595565 | GBG Forschungs GmbH|Gilead Sciences|Austrian Breast & Colorectal Cancer Study Group|Spanish Breast Cancer Research Group (GEICAM)|ETOP IBCSG Partners Foundation|Cancer Trials Ireland|UNICANCER | HER2-negative Breast Cancer|Triple Negative Breast Cancer | 2020-10-28 | PHASE3 |
| NCT04039230 | Massachusetts General Hospital|Pfizer | Breast Cancer | 2019-10-09 | PHASE1|PHASE2 |
| NCT04143711 | Dragonfly Therapeutics | Solid Tumor, Adult | 2019-11-11 | PHASE1|PHASE2 |
| NCT06428409 | Merck Sharp & Dohme LLC | Colorectal Cancer|Pancreatic Ductal Adenocarcinoma|Biliary Tract Cancer | 2024-06-20 | PHASE1|PHASE2 |
| NCT07179783 | Tianjin Medical University Second Hospital|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Prostate Cancer (Adenocarcinoma)|Prostate Cancer Metastatic Castration-Resistant|Prostate Adenocarcinoma With Neuroendocrine Differentiation | 2025-09-22 | PHASE2 |
| NCT05332561 | German Cancer Research Center | Early-stage Breast Cancer | 2023-06-29 | PHASE2 |
| NCT05867251 | Avenzo Therapeutics, Inc. | Advanced Solid Tumor|HR&addition;+HER2- Breast Cancer|HR&addition;, HER2-, Advanced Breast Cancer|CCNE1 Amplification|Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer|TNBC - Triple-Negative Breast Cancer | 2023-08-30 | PHASE1|PHASE2 |
| NCT04958785 | Gilead Sciences | Triple-Negative Breast Cancer | 2021-12-14 | PHASE2 |
| NCT05770531 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) | Metastatic HER2-Negative Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma | 2023-08-04 | PHASE2 |
| NCT07299409 | Nathalie Levasseur|British Columbia Cancer Agency | Advanced Triple Negative Breast Cancer|Breast Cancer Metastatic|Breast Cancer | 2025-12 | PHASE2 |
| NCT07178730 | West German Study Group|Gilead Sciences | Breast Cancer|Triple-negative Breast Cancer | 2026-06-30 | PHASE3 |
| NCT06393374 | Merck Sharp & Dohme LLC | Triple-Negative Breast Cancer | 2024-06-24 | PHASE3 |
| NCT06459180 | Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation | Cervical Cancer | 2024-07-24 | PHASE3 |
| NCT07359404 | YING FAN | Advanced Breast Cancer | 2024-04-01 | PHASE2 |
| NCT05097599 | Strata Oncology|Merck Sharp & Dohme LLC|Pfizer|Gilead Sciences | Cancer|Advanced Solid Tumor | 2022-04-29 | PHASE2 |
| NCT07105852 | Sir Run Run Shaw Hospital | Cholangiocarcinoma | 2025-07-03 | PHASE2 |
| NCT06780111 | Merck Sharp & Dohme LLC|Daiichi Sankyo | Esophageal Squamous Cell Carcinoma | 2025-07-30 | PHASE1|PHASE2 |
| NCT07046455 | Peking University Cancer Hospital & Institute | TNBC - Triple-Negative Breast Cancer | 2025-03-01 | NA |
| NCT05535218 | Claudia Guerrieri | Muscle-invasive Urothelial Carcinoma of the Bladder | 2023-09-20 | PHASE2 |
| NCT07375316 | Guangdong Association of Clinical Trials | Non Small Cell Lung Cancer | 2025-12-15 | PHASE2 |
| NCT05884320 | M.D. Anderson Cancer Center|Gilead Sciences | Gland|Salivary Gland Cancers | 2023-07-27 | PHASE2 |
| NCT07193160 | Fudan University | NSCLC (Non-small Cell Lung Cancer) | 2025-11-01 | PHASE2 |
| NCT07251868 | Peking University Cancer Hospital & Institute | Breast Cancer|Brain Metastases From Breast Cancer|Trop2 | 2024-08-01 | |
| NCT07328490 | National Cancer Institute (NCI) | Extensive-Stage Small Cell Lung Cancer|Extrapulmonary Neuroendocrine Carcinoma|Small Cell Carcinoma | 2026-04-25 | PHASE1|PHASE2 |
| NCT04527991 | Gilead Sciences | Locally Advanced or Metastatic Unresectable Urothelial Cancer | 2021-01-13 | PHASE3 |
| NCT06328387 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Advanced Breast Cancer|Metastatic Breast Cancer | 2024-01-29 | PHASE1|PHASE2 |
| NCT04448886 | Ana C Garrido-Castro, MD|Merck Sharp & Dohme LLC|Gilead Sciences | Invasive Breast Cancer|Metastatic Breast Cancer|HR-Positive Breast Cancer|HER2-negative Breast Cancer | 2020-09-23 | PHASE2 |
| NCT03869190 | Hoffmann-La Roche|Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas | Urothelial Carcinoma|Bladder Cancer | 2019-06-01 | PHASE1|PHASE2 |
| NCT06841354 | Merck Sharp & Dohme LLC | Triple Negative Breast Neoplasms | 2025-03-16 | PHASE3 |
| NCT03424005 | Hoffmann-La Roche|Gilead Sciences|Pfizer | Metastatic Breast Cancer | 2018-03-30 | PHASE1|PHASE2 |
| NCT07533123 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Triple Negative Breast Cancer | 2026-03-17 | PHASE3 |
| NCT05186974 | Gilead Sciences|Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer | 2022-05-30 | PHASE2 |
| NCT07438600 | Tianjin Medical University Cancer Institute and Hospital | NSCLC (Non-small Cell Lung Cancer) | 2026-02-24 | PHASE2 |
| NCT06486441 | Gilead Sciences|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Asia-Pacific Gynecologic Oncology Trials Group | Endometrial Cancer | 2024-08-28 | PHASE3 |
| NCT04724018 | Dana-Farber Cancer Institute|Gilead Sciences | Urothelial Cancer|Metastatic Urothelial Carcinoma|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Bladder Cancer | 2021-05-20 | PHASE1|PHASE2 |
| NCT07324629 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Thymic Carcinoma | 2026-06 | PHASE2 |
| NCT07501169 | Sichuan University|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 2026-04-01 | PHASE2 |
| NCT06049212 | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer|Solid Tumors|Programmed Cell Death-1 (PD1, PD-1)|Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)|Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2) | 2023-10-26 | PHASE1 |
| NCT06238921 | H. Lee Moffitt Cancer Center and Research Institute|Gilead Sciences | Breast Cancer|Triple Negative Breast Cancer | 2024-12-19 | PHASE1|PHASE2 |
| NCT06312176 | Merck Sharp & Dohme LLC | Breast Neoplasms | 2024-04-14 | PHASE3 |
| NCT06477419 | Memorial Sloan Kettering Cancer Center|Gilead Sciences | Mesothelioma|Mesotheliomas Pleural|Mesothelioma; Pleura | 2024-06-21 | PHASE2 |
| NCT07461454 | MediLink Therapeutics (Suzhou) Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 2026-03-10 | PHASE3 |
| NCT04468061 | Dana-Farber Cancer Institute|Gilead Sciences|Merck Sharp & Dohme LLC | Breast Cancer|Triple Negative Breast Cancer|PD-L1 Negative | 2020-07-20 | PHASE2 |
| NCT05609968 | Merck Sharp & Dohme LLC|Gilead Sciences | Carcinoma, Non-Small-Cell Lung | 2023-02-06 | PHASE3 |
| NCT06312137 | Merck Sharp & Dohme LLC | Non Small Cell Lung Cancer | 2024-04-03 | PHASE3 |
| NCT07504588 | National Cancer Institute (NCI) | Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma|Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma|Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma|Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma | 2026-09-10 | PHASE2 |
| NCT06305754 | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer (NSCLC) | 2024-06-11 | PHASE3 |
| NCT05008510 | Veru Inc. | Metastatic Triple Negative Breast Cancer | 2021-12-30 | PHASE2 |
| NCT07318558 | Merck Sharp & Dohme LLC | Ovarian Neoplasms|Ovarian Cancer | 2026-02-16 | PHASE3 |
| NCT06356311 | Merck Sharp & Dohme LLC | Gastroesophageal Cancer | 2024-05-03 | PHASE3 |
| NCT04794699 | IDEAYA Biosciences | Solid Tumor | 2021-04-14 | PHASE1 |
| NCT06356519 | Fudan University | Breast Cancer | 2024-03-01 | |
| NCT07108816 | Henan Cancer Hospital | Resectable Stage II-IIIB NSCLC | 2025-08-15 | PHASE2 |
| NCT06992739 | The First Affiliated Hospital of Xiamen University | NSCLC (Advanced Non-small Cell Lung Cancer)|EGFR|Myelosuppression | 2025-12-08 | PHASE2 |
| NCT05382286 | Gilead Sciences|Merck Sharp & Dohme LLC | Triple Negative Breast Cancer|PD-L1 Positive | 2022-07-25 | PHASE3 |
| NCT04826341 | National Cancer Institute (NCI) | HRD Cancer|SCLC|Advanced Solid Tumors | 2021-09-20 | PHASE1|PHASE2 |
| NCT07438626 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC | Phase II|Sacituzumab|Tirumotecan|SMARCB1-deficient Renal Medullary Carcinoma | 2026-06-01 | PHASE2 |
| NCT05581589 | University of Washington|Gilead Sciences | Muscle Invasive Bladder Carcinoma|Stage II Bladder Cancer AJCC v8|Stage IIIA Bladder Cancer AJCC v8 | 2023-06-15 | PHASE2 |
| NCT07393555 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8 | 2026-08-07 | PHASE2 |
| NCT06878625 | Tianjin Medical University Cancer Institute and Hospital | Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer | 2024-12-06 | PHASE2 |
| NCT04986579 | Dana-Farber Cancer Institute|Paxman Coolers Limited|AstraZeneca|Eisai Inc.|Daiichi Sankyo|Gilead Sciences | Metastatic Breast Cancer|Chemotherapy-induced Alopecia | 2021-10-07 | PHASE2 |
| NCT06637423 | Merck Sharp & Dohme LLC | Non-Muscle Invasive Bladder Cancer | 2024-12-20 | PHASE1|PHASE2 |
| NCT06102824 | Guangdong Provincial People´s Hospital|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-sen University|Shantou Central Hospital | HER2-negative Breast Cancer|Advanced Breast Cancer | 2024-10-01 | PHASE2 |
| NCT07256236 | Fujian Cancer Hospital | Cervical Cancer | 2026-01-28 | PHASE2 |
| NCT06445972 | Merck Sharp & Dohme LLC|Daiichi Sankyo | Gastroesophageal Junction|Gastroesophageal Adenocarcinoma|Esophageal Neoplasms|Esophageal Cancer | 2024-08-07 | PHASE1|PHASE2 |
| NCT07367178 | MedSIR | Breast Cancer|Advanced HR&addition;+HER2- Breast Cancer|Advanced Triple-Negative Breast Cancer | 2026-07 | PHASE2 |
| NCT05327530 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics | Locally Advanced or Metastatic Urothelial Carcinoma | 2022-08-17 | PHASE2 |
| NCT07163481 | Hunan Cancer Hospital|Gilead Sciences | Stage IV (Metastatic) Breast Cancer | 2025-10 | PHASE1 |
| NCT07040644 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Triple Negative Breast Neoplasms | 2025-09 | PHASE2 |
| NCT07314619 | The First Affiliated Hospital of Zhengzhou University | Platinum-resistant Recurrent Ovarian Cancer (PROC) | 2025-12-30 | PHASE2 |
| NCT06739395 | Tianjin Medical University Second Hospital | Solid Tumor|Precision Medicine | 2024-11-01 | PHASE2 |
| NCT04319198 | Gilead Sciences | Metastatic Solid Tumors | 2020-08-04 | PHASE4 |
| NCT07244926 | Tianjin Medical University Cancer Institute and Hospital | Lung Cancer | 2025-12 | PHASE2 |
| NCT07197008 | Li-kun Chen | Lung Cancer | 2025-10-01 | PHASE2 |
| NCT04251416 | Yale University|Gilead Sciences | Endometrial Carcinoma | 2020-03-17 | PHASE2 |
| NCT06123468 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Gilead Sciences | Esophagogastric Adenocarcinoma | 2024-04-17 | PHASE1|PHASE2 |
| NCT06028932 | Yale University|Gilead Sciences | Ovarian Carcinoma | 2024-01-08 | PHASE2 |
| NCT04559230 | The University of Texas Health Science Center at San Antonio | Recurrent Glioblastoma | 2022-01-06 | PHASE2 |
| NCT06167317 | Gilead Sciences | Advanced Solid Tumors | 2024-01-09 | PHASE1 |
| NCT07511023 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC | Phase 2|Sacituzumab Tirumotecan|Refractory Metastatic|Unresectable Squamous|Cell Carcinoma of the Anus+ Rectum | 2026-09-25 | PHASE2 |
| NCT06081244 | West German Study Group|Gilead Sciences|Merck Sharp & Dohme LLC | Triple Negative Breast Cancer | 2024-10-10 | PHASE3 |
| NCT06966700 | Merck Sharp & Dohme LLC | Breast Neoplasms|Triple Negative Breast Neoplasms|HR Low-Positive+HER2-Negative Breast Neoplasms | 2025-06-30 | PHASE3 |
| NCT07419295 | Merck Sharp & Dohme LLC | Bladder Cancer | 2026-04-23 | PHASE3 |
| NCT05006794 | Gilead Sciences | Solid Malignancies | 2021-09-15 | PHASE1 |
| NCT06801834 | Gilead Sciences | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 2025-04-04 | PHASE3 |